Accès gratuit
Med Sci (Paris)
Volume 18, Numéro 3, Mars 2002
Page(s) 335 - 342
Section M/S Revues : Articles de Synthèse
Publié en ligne 15 mars 2002
  1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340 : 745–50.
  2. Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995; 22 : 1027–33.
  3. Tsai J, Jeng J, Ho M, et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997; 76 : 968–74.
  4. De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995; 345 : 413–5.
  5. Grando-Lemaire V, Guettier C, Chevret S, Beaugrand M, Trinchet JC. Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver. Groupe d’étude et de traitement du carcinome hépatocellulaire. J Hepatol 1999; 31 : 508–13.
  6. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47 : 131–6.
  7. Paradis V, Laurendeau I, Vidaud M, Bedossa P. Clonal analysis of macronodules in cirrhosis. Hepatology 1998; 28 : 953–8.
  8. Debuire B, Paterlini P, Pontisso P, Basso G, May E. Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene 1993; 8 : 2303–6.
  9. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350 : 427–8.
  10. Caruso ML, Valentini AM. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation. Anticancer Res 1999; 19 : 3853–6
  11. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120 : 1763–73.
  12. Kawai H, Suda T, Aoyagi Y, et al. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology 2000; 31 : 1246–50.
  13. Kusano N, Shiraishi K, Kubo K, Oga A, Okita K, Sasaki K. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 1999; 29 : 1858–62.
  14. Okabe H, Ikai I, Matsuo K, et al. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. Hepatology 2000; 31 : 1073–9.
  15. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998; 95 : 8847–51.
  16. Kozyraki R, Scoazec JY, Flejou JF, et al. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. Gastroenterology 1996; 110 : 1137–49.
  17. Bukh J , Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 1994; 91 : 8239–43.
  18. Cerino A, Boender P, La Monica N, Rosa C, Habets W, Mondelli MU. A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein. J Immunol 1993; 151 : 7005–15.
  19. Barba G, Harper T, Harada M, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94 : 1200–5.
  20. Sabile A, Perlemuter G, Bono F, et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 1999; 30 : 1064–76.
  21. Chen CM, You LR, Hwang LH, Lee YH. Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. J Virol 1997; 71 : 9417–26.
  22. Zhu N , Khoshnan A , Schneider R , et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998; 72 : 3691–7.
  23. Jin DY, Wang HL, Zhou Y, et al. Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. EMBO J 2000; 19 : 729–40.
  24. Ray RB, Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997; 272 : 10983–6.
  25. Ray RB, Steele R, Meyer K, Ray R. Hepatitis C virus core protein represses p21waf1/Cip1/Sid1 promoter activity. Gene 1998; 208 : 331–6.
  26. Kozyraki R, Scoazec JY, Flejou JF, et al. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. Gastroenterology 1996; 110 : 1137–49.
  27. Lu W, Lo SY, Chen M, Wu KJ, Fung YK, Ou JH. Activation of p53 tumor suppressor by hepatitis C virus core protein. Virology 1999; 264 : 134–41.
  28. Shi YZ, Hui AM, Takayama T, Li X, Cui X, Makuuchi M. Reduced p21(Waf1/Cips1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas. Br J Cancer 2000; 83 : 50–5.
  29. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285 : 107–10.
  30. Borowski P, Oehlman K, Heiland M, Laufs R. Nonstructural protein 3 of hepatitis C virus blocks the distribution of the free catalytic subunit of cyclic AMP-dependent protein kinase. J Virol 1997; 71 : 2838–43.
  31. Gale MJ, Korth M, Tang NM, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230 : 217–27.
  32. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001; 75 : 1401–7.
  33. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995; 69 : 3893–6.
  34. Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78 : 1527–31.
  35. Hiramatsu N, Hayashi N, Katayama K, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19 : 1354–9.
  36. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol 1999; 73 : 4713–20.
  37. Yoshida H, Kato N, Shiratori Y, et al. Hepatitis C virus core protein activates NF-κB-dependent signaling through tumor necrosis factor receptor-associated factor. J Biol Chem 2001; 212 : 451–62.
  38. Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001; 120 : 955–66.
  39. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122 : 161–8.
  40. Ruster B, Zeuzem S, Roth WK. Hepatitis C virus sequences encoding truncated core proteins detected in a hepatocellular carcinoma. Biochem Biophys Res Commun 1996; 219 : 911–5.
  41. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346 : 1051–5.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.